These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3858583)

  • 21. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
    Bercu JP; Hoffman WP; Lee C; Ness DK
    Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Open Field Test: reinventing the wheel.
    Stanford SC
    J Psychopharmacol; 2007 Mar; 21(2):134-5. PubMed ID: 17329288
    [No Abstract]   [Full Text] [Related]  

  • 23. [Current status of the problem of testing drugs for carcinogenicity].
    Shashkina LF; Ivanova VM; Liubimov BI
    Farmakol Toksikol; 1985; 48(3):107-13. PubMed ID: 3896842
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term and short-term screening assays for carcinogens: a critical appraisal.
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):1-426. PubMed ID: 6935176
    [No Abstract]   [Full Text] [Related]  

  • 25. Carcinogen testing & public information.
    Upton AC
    Hastings Cent Rep; 1980 Feb; 10(1):9-10. PubMed ID: 7372460
    [No Abstract]   [Full Text] [Related]  

  • 26. IARC monograph programme on the evaluation of the carcinogenic risk of chemicals to humans.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1978 Oct; 18():15-35. PubMed ID: 282232
    [No Abstract]   [Full Text] [Related]  

  • 27. Studies on the mechanism of the synergistic carcinogenic response reported between ethylene and disulfiram and the implications for short term predictive screening tests.
    Elliott BM; Ashby J
    Dev Toxicol Environ Sci; 1980; 8():193-6. PubMed ID: 7030702
    [No Abstract]   [Full Text] [Related]  

  • 28. [Control, drug preparation and dosage in the designing of experiments (author's transl)].
    Chen X
    Zhonghua Yi Xue Za Zhi; 1981 Jun; 61(6):335-8. PubMed ID: 6796231
    [No Abstract]   [Full Text] [Related]  

  • 29. DNA damage and repair in mammalian cells.
    Williams GM; Bordet C; Cerutti PA; Fuchs RP; Laval J; Lu SH; Parodi S; Pegg AE; Rajewsky MF
    IARC Monogr Eval Carcinog Risk Chem Hum Suppl; 1980; (2 Suppl):201-26. PubMed ID: 6935179
    [No Abstract]   [Full Text] [Related]  

  • 30. Toward a classification scheme for degrees of experimental evidence for the carcinogenicity of chemicals for animals.
    Griesemer RA; Cueto C
    IARC Sci Publ; 1980; (27):259-81. PubMed ID: 6893701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in multivariate analysis in pharmaceutical process development.
    McKay B; Hoogenraad M; Damen EW; Smith AA
    Curr Opin Drug Discov Devel; 2003 Nov; 6(6):966-77. PubMed ID: 14758764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to "use of Statistics when Examining Lifetime Studies in Rodents to Detect Carcinogenicity".
    Fears TR; Tarone RE
    J Toxicol Environ Health; 1977 Nov; 3(4):629-32. PubMed ID: 592430
    [No Abstract]   [Full Text] [Related]  

  • 33. Of rodents, humankind, and cholesterol.
    Lindenmayer JM
    Med Health R I; 1996 Apr; 79(4):148-50. PubMed ID: 8857410
    [No Abstract]   [Full Text] [Related]  

  • 34. Induction of resistant hepatocytes as a new principle for a possible short-term in vivo test for carcinogens.
    Tsuda H; Lee G; Farber E
    Cancer Res; 1980 Apr; 40(4):1157-64. PubMed ID: 6101993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of results of agglutination assays with concanavalin A and carcinogenesis experiments on promoters of bladder cancer.
    Kakizoe T; Nishio Y; Ohtani M; Niijima T; Sato S; Sugimura T
    Jpn J Cancer Res; 1985 Oct; 76(10):930-6. PubMed ID: 3935624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of the application of response surface methodology in the combination therapy of cancer.
    Carter WH; Wampler GL
    Cancer Treat Rep; 1986 Jan; 70(1):133-40. PubMed ID: 3943113
    [No Abstract]   [Full Text] [Related]  

  • 37. New screening tools for lead compound identification.
    Sawyer TK
    Nat Chem Biol; 2005 Aug; 1(3):125. PubMed ID: 16408012
    [No Abstract]   [Full Text] [Related]  

  • 38. The predictability of bioassays.
    Anderson D
    Prog Clin Biol Res; 1982; 109():149-68. PubMed ID: 6891964
    [No Abstract]   [Full Text] [Related]  

  • 39. Evaluations of organ system development in juvenile toxicology testing.
    Robinson K
    Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary; re FDA reissues proposal for evaluating assays for carcinogenic compounds.
    Jones LD
    Vet Hum Toxicol; 1979 Aug; 21(4):296-7. PubMed ID: 494489
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.